Fatal Outcome of COVID-19 Relapse in a Fully Vaccinated Patient with Non-Hodgkin Lymphoma Receiving Maintenance Therapy with the Anti-CD20 Monoclonal Antibody Obinutuzumab: A Case Report

Few data are available regarding the effectiveness of anti-SARS-CoV-2 vaccine in immunocompromised patients. Vaccination may have a suboptimal efficacy in this population, in particular if patients are exposed to anti-B-cell therapy. We report the virological and clinical characteristics of a patien...

Descripción completa

Detalles Bibliográficos
Autores principales: Calò, Federica, Onorato, Lorenzo, Pisaturo, Mariantonietta, Pinto, Antonio, Alessio, Loredana, Monari, Caterina, Minichini, Carmine, Arcamone, Manuela, Di Fraia, Alessandra, Atripaldi, Luigi, Tiberio, Claudia, Coppola, Nicola
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9323164/
https://www.ncbi.nlm.nih.gov/pubmed/35891185
http://dx.doi.org/10.3390/vaccines10071021
_version_ 1784756483334864896
author Calò, Federica
Onorato, Lorenzo
Pisaturo, Mariantonietta
Pinto, Antonio
Alessio, Loredana
Monari, Caterina
Minichini, Carmine
Arcamone, Manuela
Di Fraia, Alessandra
Atripaldi, Luigi
Tiberio, Claudia
Coppola, Nicola
author_facet Calò, Federica
Onorato, Lorenzo
Pisaturo, Mariantonietta
Pinto, Antonio
Alessio, Loredana
Monari, Caterina
Minichini, Carmine
Arcamone, Manuela
Di Fraia, Alessandra
Atripaldi, Luigi
Tiberio, Claudia
Coppola, Nicola
author_sort Calò, Federica
collection PubMed
description Few data are available regarding the effectiveness of anti-SARS-CoV-2 vaccine in immunocompromised patients. Vaccination may have a suboptimal efficacy in this population, in particular if patients are exposed to anti-B-cell therapy. We report the virological and clinical characteristics of a patient with follicle center lymphoma under bimonthly maintenance therapy with obinutuzumab, an anti-CD20 monoclonal antibody. Despite three doses of BNT162b2 vaccine, the patient was infected by the SARS-CoV-2 Omicron variant. After an initial period of clinical and molecular remission due to early therapy with sotrovimab, the patient experienced a fatal relapse sustained by the same viral strain.
format Online
Article
Text
id pubmed-9323164
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-93231642022-07-27 Fatal Outcome of COVID-19 Relapse in a Fully Vaccinated Patient with Non-Hodgkin Lymphoma Receiving Maintenance Therapy with the Anti-CD20 Monoclonal Antibody Obinutuzumab: A Case Report Calò, Federica Onorato, Lorenzo Pisaturo, Mariantonietta Pinto, Antonio Alessio, Loredana Monari, Caterina Minichini, Carmine Arcamone, Manuela Di Fraia, Alessandra Atripaldi, Luigi Tiberio, Claudia Coppola, Nicola Vaccines (Basel) Case Report Few data are available regarding the effectiveness of anti-SARS-CoV-2 vaccine in immunocompromised patients. Vaccination may have a suboptimal efficacy in this population, in particular if patients are exposed to anti-B-cell therapy. We report the virological and clinical characteristics of a patient with follicle center lymphoma under bimonthly maintenance therapy with obinutuzumab, an anti-CD20 monoclonal antibody. Despite three doses of BNT162b2 vaccine, the patient was infected by the SARS-CoV-2 Omicron variant. After an initial period of clinical and molecular remission due to early therapy with sotrovimab, the patient experienced a fatal relapse sustained by the same viral strain. MDPI 2022-06-26 /pmc/articles/PMC9323164/ /pubmed/35891185 http://dx.doi.org/10.3390/vaccines10071021 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Case Report
Calò, Federica
Onorato, Lorenzo
Pisaturo, Mariantonietta
Pinto, Antonio
Alessio, Loredana
Monari, Caterina
Minichini, Carmine
Arcamone, Manuela
Di Fraia, Alessandra
Atripaldi, Luigi
Tiberio, Claudia
Coppola, Nicola
Fatal Outcome of COVID-19 Relapse in a Fully Vaccinated Patient with Non-Hodgkin Lymphoma Receiving Maintenance Therapy with the Anti-CD20 Monoclonal Antibody Obinutuzumab: A Case Report
title Fatal Outcome of COVID-19 Relapse in a Fully Vaccinated Patient with Non-Hodgkin Lymphoma Receiving Maintenance Therapy with the Anti-CD20 Monoclonal Antibody Obinutuzumab: A Case Report
title_full Fatal Outcome of COVID-19 Relapse in a Fully Vaccinated Patient with Non-Hodgkin Lymphoma Receiving Maintenance Therapy with the Anti-CD20 Monoclonal Antibody Obinutuzumab: A Case Report
title_fullStr Fatal Outcome of COVID-19 Relapse in a Fully Vaccinated Patient with Non-Hodgkin Lymphoma Receiving Maintenance Therapy with the Anti-CD20 Monoclonal Antibody Obinutuzumab: A Case Report
title_full_unstemmed Fatal Outcome of COVID-19 Relapse in a Fully Vaccinated Patient with Non-Hodgkin Lymphoma Receiving Maintenance Therapy with the Anti-CD20 Monoclonal Antibody Obinutuzumab: A Case Report
title_short Fatal Outcome of COVID-19 Relapse in a Fully Vaccinated Patient with Non-Hodgkin Lymphoma Receiving Maintenance Therapy with the Anti-CD20 Monoclonal Antibody Obinutuzumab: A Case Report
title_sort fatal outcome of covid-19 relapse in a fully vaccinated patient with non-hodgkin lymphoma receiving maintenance therapy with the anti-cd20 monoclonal antibody obinutuzumab: a case report
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9323164/
https://www.ncbi.nlm.nih.gov/pubmed/35891185
http://dx.doi.org/10.3390/vaccines10071021
work_keys_str_mv AT calofederica fataloutcomeofcovid19relapseinafullyvaccinatedpatientwithnonhodgkinlymphomareceivingmaintenancetherapywiththeanticd20monoclonalantibodyobinutuzumabacasereport
AT onoratolorenzo fataloutcomeofcovid19relapseinafullyvaccinatedpatientwithnonhodgkinlymphomareceivingmaintenancetherapywiththeanticd20monoclonalantibodyobinutuzumabacasereport
AT pisaturomariantonietta fataloutcomeofcovid19relapseinafullyvaccinatedpatientwithnonhodgkinlymphomareceivingmaintenancetherapywiththeanticd20monoclonalantibodyobinutuzumabacasereport
AT pintoantonio fataloutcomeofcovid19relapseinafullyvaccinatedpatientwithnonhodgkinlymphomareceivingmaintenancetherapywiththeanticd20monoclonalantibodyobinutuzumabacasereport
AT alessioloredana fataloutcomeofcovid19relapseinafullyvaccinatedpatientwithnonhodgkinlymphomareceivingmaintenancetherapywiththeanticd20monoclonalantibodyobinutuzumabacasereport
AT monaricaterina fataloutcomeofcovid19relapseinafullyvaccinatedpatientwithnonhodgkinlymphomareceivingmaintenancetherapywiththeanticd20monoclonalantibodyobinutuzumabacasereport
AT minichinicarmine fataloutcomeofcovid19relapseinafullyvaccinatedpatientwithnonhodgkinlymphomareceivingmaintenancetherapywiththeanticd20monoclonalantibodyobinutuzumabacasereport
AT arcamonemanuela fataloutcomeofcovid19relapseinafullyvaccinatedpatientwithnonhodgkinlymphomareceivingmaintenancetherapywiththeanticd20monoclonalantibodyobinutuzumabacasereport
AT difraiaalessandra fataloutcomeofcovid19relapseinafullyvaccinatedpatientwithnonhodgkinlymphomareceivingmaintenancetherapywiththeanticd20monoclonalantibodyobinutuzumabacasereport
AT atripaldiluigi fataloutcomeofcovid19relapseinafullyvaccinatedpatientwithnonhodgkinlymphomareceivingmaintenancetherapywiththeanticd20monoclonalantibodyobinutuzumabacasereport
AT tiberioclaudia fataloutcomeofcovid19relapseinafullyvaccinatedpatientwithnonhodgkinlymphomareceivingmaintenancetherapywiththeanticd20monoclonalantibodyobinutuzumabacasereport
AT coppolanicola fataloutcomeofcovid19relapseinafullyvaccinatedpatientwithnonhodgkinlymphomareceivingmaintenancetherapywiththeanticd20monoclonalantibodyobinutuzumabacasereport

Ejemplares similares